iStent inject W, iStent infinite , and KXL system belong to the focus of Glaukos, an ophthalmic medical technology company dedicated to transforming the treatment of chronic eye diseases, particularly glaucoma. These products are designed to
...
provide innovative therapies that enhance patient outcomes and address significant clinical needs. The company emphasizes the development of non-drop platforms, which aim to improve treatment standards in ophthalmology. Glaukos is committed to investing 35% of its net revenue into research and development, highlighting its dedication to continuous innovation in the field. Furthermore, the KXL system utilizes riboflavin for corneal cross-linking procedures, which help slow or halt the progression of keratoconus, thereby preserving vision. With a presence in multiple countries, including Australia, Canada, and the United Kingdom, Glaukos aims to ensure wider access to effective ophthalmic care. This commitment to advancing medical technology is central to Glaukos's mission of improving visual health for patients worldwide.
